Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. X4 Pharmaceuticals Inc shares valued at $2,561 were purchased by Baldry Mark on May 16 ’25. At $2.48 per share, Baldry Mark acquired 1,032 shares. The insider’s holdings grew to 25,337 shares worth approximately $71450.34 following the completion of this transaction.
Also, Baldry Mark purchased 13,404 shares, netting a total of over 4,598 in proceeds. Following the buying of shares at $0.34 each, the insider now holds 129,173 shares.
Before that, Ragan Paula had sold 76,473 shares from its account. In a trade valued at $34,719, the President and CEO traded X4 Pharmaceuticals Inc shares for $0.45 each. Upon closing the transaction, the insider’s holdings decreased to 76,473 shares, worth approximately $3.07 million.
As published in a research note from B. Riley Securities on December 12, 2023, X4 Pharmaceuticals Inc [XFOR] has been rated down from a Buy to a Neutral and the price target has been revised to $1 from $3. As of December 22, 2022, Cantor Fitzgerald has initiated its “an Overweight” rating for XFOR. Earlier on December 12, 2022, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for XFOR stock.
Analyzing XFOR Stock Performance
On last trading session,, X4 Pharmaceuticals Inc [NASDAQ: XFOR] rose 2.92% to $2.82. During the last five days, there has been a drop of approximately -12.01%. Over the course of the year, X4 Pharmaceuticals Inc shares have dropped approximately -87.19%. Shares of the company reached a 52-week high of $24.44 on 01/02/25 and a 52-week low of $2.62 on 06/17/25.
Support And Resistance Levels for X4 Pharmaceuticals Inc (XFOR)
According to the 24-hour chart, there is a support level at 2.69, which, if violated, would cause prices to drop to 2.57. In the upper region, resistance lies at 2.96. The next price resistance is at 3.11. RSI (Relative Strength Index) is 37.01 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of X4 Pharmaceuticals Inc (XFOR)?
In terms of X4 Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 3 in the next 12 months, up nearly 9.49% from the previous closing price of $2.74. Analysts anticipate X4 Pharmaceuticals Inc stock to reach 5 by 2025, with the lowest price target being 3. In spite of this, 3 analysts ranked X4 Pharmaceuticals Inc stock as Buy at the end of 2025. On December 23, 2019, Oppenheimer assigned a price target of “an Outperform” to the stock and initiated coverage with a $20.
